Evidence map›Paper›PMID 34802051›Full record

Trial reportBritish journal of cancer2022

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.

Cristina Gasparetto, Gary J Schiller, Sascha A Tuchman, Natalie S Callander, Muhamed Baljevic, Suzanne Lentzsch, Adriana C Rossi, Rami Kotb, Darrell White, Nizar J Bahlis and 19 more

Abstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. The numerous facets of 1q21Oncology letters · 2024
    Review
  14. Review
  15. Treatment of multiple myeloma with selinexor: a review.Therapeutic advances in hematology · 2024
    Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Cristina GasparettoDuke University Medical Center, Durham, NC, USA. cristina.gasparetto@duke.edu.ORCID http://orcid.org/0000-0003-1513-5605
Gary J SchillerDavid Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Sascha A TuchmanUniversity of North Carolina, Chapel Hill, NC, USA.
Natalie S CallanderCarbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA.
Muhamed BaljevicUniversity of Nebraska Medical Center, Omaha, NE, USA.
Suzanne LentzschColombia University, New York, NY, USA.
Adriana C RossiNYPH Weill Cornell, New York, NY, USA.
Rami KotbCancer Care Manitoba, Winnipeg, MB, Canada.
Darrell WhiteDalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.
Nizar J BahlisCharbonneau Cancer Research Institute, Calgary, AB, Canada.
Christine I ChenDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Heather J SutherlandVancouver General Hospital, Vancouver, BC, Canada.
Sumit MadanBanner MD Anderson Cancer Center, Gilbert, AZ, USA.
Richard LeBlancMaisonneuve-Rosemont Hospital, University of Montreal, Montreal, QC, Canada.
Michael SebagRoyal Victoria Hospital, Montreal, QC, Canada.
Christopher P VennerCross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
William I BensingerMyeloma and Transplant Program, Swedish Cancer Institute, Seattle, WA, USA.
Noa BiranHackensack Meridian Health, Hackensack University Medical Center, Teaneck, USA.
Sonia AmmuKaryopharm Therapeutics Inc., Newton, MA, USA.
Osnat Ben-ShaharKaryopharm Therapeutics Inc., Newton, MA, USA.
Andrew DeCastroKaryopharm Therapeutics Inc., Newton, MA, USA.
Dane Van DomelenKaryopharm Therapeutics Inc., Newton, MA, USA.
Tianjun ZhouKaryopharm Therapeutics Inc., Newton, MA, USA.
Chris ZhangKaryopharm Therapeutics Inc., Newton, MA, USA.
Ohad S BenturKaryopharm Therapeutics Inc., Newton, MA, USA.
Jatin ShahKaryopharm Therapeutics Inc., Newton, MA, USA.
Sharon ShachamKaryopharm Therapeutics Inc., Newton, MA, USA.
Michael KauffmanKaryopharm Therapeutics Inc., Newton, MA, USA.
Brea LipeUniversity of Rochester Medical College, Rochester, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProteasome inhibitors (PIs), including carfilzomib, potentiate the activity of selinexor, a novel, first-in-class, oral selective inhibitor of nuclear export (SINE) compound, in preclinical models of multiple myeloma (MM).

methodsThe safety, efficacy, maximum-tolerated dose (MTD) and recommended phase 2 dose (RP2D) of selinexor (80 or 100 mg) + carfilzomib (56 or 70 mg/m

resultsThirty-two patients, median prior therapies 4 (range, 1-8), were enrolled. MM was triple-class refractory in 38% of patients and 53% of patients had high-risk cytogenetics del(17p), t(4;14), t(14;16) and/or gain 1q. Common treatment-related adverse events (all/Grade 3) were thrombocytopenia 72%/47% (G3 and G4), nausea 72%/6%, anaemia 53%/19% and fatigue 53%/9%, all expected and manageable with supportive care and dose modifications. MTD and RP2D were identified as selinexor 80 mg, carfilzomib 56 mg/m

conclusionsWeekly XKd is highly effective and well-tolerated. These data support further investigation of XKd in patients with MM.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneDrug Administration ScheduleFemaleHumansHydrazinesMaleMaximum Tolerated DoseMiddle AgedMultiple MyelomaOligopeptidesSurvival AnalysisTranslocation, GeneticTreatment OutcomecarfilzomibDexamethasoneHydrazinesOligopeptidesselinexorTriazoles

Identifiers

PMID34802051
PMCPMC8605887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.